Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Ticker: RVMD
Exchange: Nasdaq
Sector: Healthcare
Industry: Biotechnology
Market cap: $41.58B
52-week range: $58.91 - $224.31

Valuation

Share price: $192.28 (close of Nov 6, 2026)
P/E (TTM): -21.01x
Price to book: 17.31x
Price to free cash flow: -28.86x
Enterprise value: $41.60B
Book value per share: $11.11

Price performance

Period	Change
1 day	+8.24%
5 days	+0.51%
1 month	-3.80%
3 months	-2.80%
6 months	+27.28%
Year to date	+141.41%
1 year	+213.26%
3 years	+792.66%
5 years	+470.56%
All time	+565.33%

Short interest

As of: Oct 15, 2026
Short % of float: 6.37%
Shares short: 12.93M
Days to cover: 6.13
Change since prior report: +8.46%
Source: FINRA consolidated short interest

Profitability and growth

Return on equity: -69.35%
Return on invested capital: -66.05%
Return on assets: -48.05%
Return on capital employed: -57.28%

Cash flow and balance sheet

Free cash flow yield (TTM): -3.47%
Current ratio: 8.36x
Net debt to EBITDA: -0.01x

Latest reported year

Period end: Dec 31, 2025
Fiscal year: 2025
EBITDA: -$1.17B
Net income: -$1.13B
Earnings per share: $-5.95
Research and development: $987.33M
Interest expense: $24.23M
Shares outstanding: 190.13M

Income statement by year

Period end	Revenue	Net income	EPS
2025-12-31	-	-$1.13B	-$5.95
2024-12-31	-	-$600.09M	-$3.58
2023-12-31	$11.58M	-$436.37M	-$3.86
2022-12-31	$35.38M	-$248.71M	-$3.08
2021-12-31	$29.39M	-$187.09M	-$2.57
2020-12-31	$42.98M	-$108.16M	-$2.01
2019-12-31	$50.04M	-$47.66M	-$22.33
2018-12-31	$20.16M	-$41.79M	-$21.24

Margins and returns by year

Period end	Net margin	Return on equity	Return on capital
2025-12-31	-	-69.35%	-66.05%
2024-12-31	-	-26.49%	-28.69%
2023-12-31	-3,768.28%	-23.89%	-25.27%
2022-12-31	-702.95%	-36.30%	-34.41%
2021-12-31	-636.58%	-31.05%	-28.09%
2020-12-31	-251.63%	-22.79%	-21.75%
2019-12-31	-95.25%	-	-
2018-12-31	-207.24%	-	-

Cash and debt by year

Period end	Cash
2025-12-31	$383.75M
2024-12-31	$543.06M
2023-12-31	$696.15M
2022-12-31	$161.41M
2021-12-31	$108.50M
2020-12-31	$104.27M
2019-12-31	$16.66M
2018-12-31	$69.59M
2017-12-31	$9.08M

Free cash flow by year

Period end	Free cash flow	Stock-based compensation
2025-12-31	-$913.73M	$118.39M
2024-12-31	-$567.74M	$79.20M
2023-12-31	-$358.30M	$61.77M
2022-12-31	-$235.22M	$31.20M
2021-12-31	-$153.71M	$20.72M
2020-12-31	-$103.00M	$8.89M
2019-12-31	-$52.20M	$3.16M
2018-12-31	-$286.00K	$855.00K
2017-12-31	-$26.72M	$141.00K

Investor relations

Past earnings dates

Reported	Fiscal period	EPS estimate
2026-11-04	Sep 2026	-$2.34
2026-08-05	Jun 2026	-$1.93
2026-05-06	Mar 2026	-$1.83
2026-02-25	Dec 2025	-$1.56
2025-11-05	Sep 2025	-$1.39
2025-08-06	Jun 2025	-$0.94
2025-05-07	Mar 2025	-$1.12
2025-02-26	Dec 2024	-$0.99

Filings and sources

Company website: revmed.com
SEC filings: 10-K, 10-Q and 8-K on EDGAR
Earnings calendar: All upcoming reports

Similar companies

Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Insmed Inc (INSM) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades